First-Line Therapy for Advanced RCC: Optimizing Adverse Event Management
A brief review of common adverse events inherent in the first-line management of advanced renal cell carcinoma and practical advice on how to mitigate treatment toxicity.
Overview of First-Line Treatment Options for Advanced RCC
Opening their discussion on the advanced renal cell carcinoma treatment landscape, experts Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, identify cornerstone first-line regimens.
Carriers of CHEK2 Mutations Have a 2-Fold Increased Risk for Contralateral Breast Cancer, Says Expert
An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.
Investigational Treatment Approach Effective, Safe and Inexpensive in a Type of Prostate Cancer, Says Expert
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
HER2CLIMB: Role of Tucatinib in Treating HER2+ mBC With CNS Disease
A panel of expert oncologists highlight the use of the tucatinib, trastuzumab and capecitabine regimen that was investigated in the HER2CLIMB trial to manage patients with HER2+ breast cancer and brain metastases.
HER2+ Metastatic Breast Cancer: Role of Radiation Therapy in Managing CNS Disease
Expert perspectives on the respective role of radiation therapy to manage brain metastases in the setting of HER2+ breast cancer.
Many Unanswered Questions About Risks for Contralateral Breast Cancer Led to CARRIERS Study, Says Expert
An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.
Multiple Molecular Mechanisms May Drive Responses to Investigational Prostate Cancer Treatment, Expert Says
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
Overview of BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory MM
A broad perspective on the development of BCMA-targeted bispecific antibodies for patients with relapsed/refractory multiple myeloma.
Patient Case 1: Relapsed/Refractory MM Managed With Teclistamab
Centering discussion on two clinical cases of patients with relapsed/refractory multiple myeloma, expert panelists highlight the use of BCMA-targeted teclistamab in this setting.
‘Absolutely Important’ to Develop Better Ways to Predict Kidney Cancer Recurrence, Says Expert
Future research must address ways to improve the prediction of kidney cancer recurrence to better inform patients, says an expert from the Royal Free London NHS Foundation Trust.
Role of Immunotherapies in Microsatellite Stable Metastatic CRC
Shared insight on the potential role for immunotherapeutic agents in the setting of microsatellite stable metastatic colorectal cancer.
Updates in the Management of KRASG12C-Mutated Metastatic CRC
Centering discussion on KRASG12C-mutated metastatic colorectal cancer, panelists highlight recent clinical studies of targeted agents in this subset of disease.
Why European Experts Cautiously Recommend Pembrolizumab to Treat High-Risk Kidney Cancer Following Surgery
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Highlighting Ongoing Clinical Trials in CML From ASH
Kendra Sweet, MD, discussed several ongoing studies in chronic myeloid leukemia, with some initial results presented at the 2022 American Society of Hematology Annual Meeting and Exposition.
‘Number of Unanswered Questions’ Remain About Role of Stereotactic Radiation in Metastatic Kidney Cancer
An expert from the University of Texas Southwestern Medical Center questions how providers are currently utilizing stereotactic radiation in the treatment of metastatic kidney cancer.
Urologists Should Make Patients With Metastatic Kidney Cancer Aware that not All Trials Have Positive Results, Says Expert
Patients with kidney cancer should be made aware of trials that have not read out positively in the adjuvant setting, according to an expert from the Royal Free London NHS Foundation Trust.
The Implications of CML Data From ASH, And Important Takeaways for Providers
Kendra Sweet, MD, examined how the data surrounding asciminib in chronic myeloid leukemia will affect the standard of care treatment options.
How Ponatinib Factors into the Treatment of a Type of Leukemia
Kendra Sweet, MD, discussed results of the the phase 2 OPTIC trial, which investigated ponatinib in a group of patients with resistant, chronic phase chronic myeloid leukemia.
Factors in Selecting Therapy for HER2+ Metastatic Breast Cancer With CNS Disease
Shared consideration on the factors that dictate selection of optimal therapy for patients with HER2+ breast cancer and brain metastases.
